Know Cancer

or
forgot password

Phase II Evaluation of Gleevec Combined With Camptosar Plus Paraplatin in Patients With Previously Untreated Extensive Stage SCLC


Phase 2
18 Years
N/A
Not Enrolling
Both
Lung Cancer

Thank you

Trial Information

Phase II Evaluation of Gleevec Combined With Camptosar Plus Paraplatin in Patients With Previously Untreated Extensive Stage SCLC


Upon determination of eligibility, all patients will be receive:

- Irinotecan + Carboplatin + Imatinib


Inclusion Criteria:



To be included in this study, you must meet the following criteria:

- Small cell lung cancer with extensive stage disease confirmed by biopsy

- Measurable or evaluable disease

- Ability to perform activities of daily living with minimal assistance

- Adequate bone marrow, liver and kidney

- No active brain metastasis.

- No previous chemotherapy or radiation therapy

- Give written informed consent.

Exclusion Criteria:

You cannot participate in this study if any of the following apply to you:

- Limited stage disease (includes IA, IB, IIA, IIB, and IIIA)

- Active brain metastasis

- Age < 18 years old

- History of a prior malignancy within three years

- Women pregnant or lactating.

Please note: There are additional inclusion/exclusion criteria. The study center will
determine if you meet all of the criteria. If you do not qualify for the trial, study
personnel will explain the reasons. If you do qualify, study personnel will explain the
trial in detail and answer any questions you may have.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Overall response rate

Principal Investigator

Anthony Greco, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Sarah Cannon Research Institute

Authority:

United States: Food and Drug Administration

Study ID:

SCRI LUN 59

NCT ID:

NCT00193349

Start Date:

September 2002

Completion Date:

December 2007

Related Keywords:

  • Lung Cancer
  • Lung Neoplasms
  • Small Cell Lung Carcinoma

Name

Location